{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:46Z","timestamp":1792783066296,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Cedars-Sinai Medical Center","id":[{"id":"https:\/\/ror.org\/02pammg90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10620-026-10112-7","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:32:00Z","timestamp":1783517520000},"page":"5405-5415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study"],"prefix":"10.1007","volume":"71","author":[{"given":"Piyush","family":"Nathani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevag","family":"Hamamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jena","family":"Velji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Nathani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvil","family":"Radadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarnav","family":"Shandilya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Repici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"10112_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399:394\u2013405.","journal-title":"Lancet."},{"key":"10112_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819\u2013837.","journal-title":"Cell Metab."},{"key":"10112_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022;23:e13435.","journal-title":"Obes Rev."},{"key":"10112_CR4","unstructured":"Administration USFaD. Saxenda (liraglutide) injection, for subcutaneous use. Novo Nordisk; 2014. Report No.: NDA 206321."},{"key":"10112_CR5","unstructured":"Administration USFaD. Wegovy (semaglutide) injection, for subcutaneous use: Prescribing information. Novo Nordisk; 2021."},{"key":"10112_CR6","unstructured":"Administration USFaD. Zepbound (tirzepatide) injection, for subcutaneous use: Prescribing information. Silver Spring, MD: Eli Lilly; 2023. Report No.: NDA 217806."},{"key":"10112_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613\u2013626.","journal-title":"Lancet."},{"key":"10112_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. Jama. 2022;327:138\u2013150.","journal-title":"Jama."},{"key":"10112_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Jama. 2021;325:1403\u20131413.","journal-title":"Jama."},{"key":"10112_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u2013984.","journal-title":"Lancet."},{"key":"10112_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med."},{"key":"10112_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med."},{"key":"10112_CR13","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Jama. 2023;330:1795\u20131797.","journal-title":"Jama."},{"key":"10112_CR14","doi-asserted-by":"publisher","first-page":"232470962110519","DOI":"10.1177\/23247096211051919","volume":"9","author":"MA Kalas","year":"2021","unstructured":"Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051920.","journal-title":"J Investig Med High Impact Case Rep."},{"key":"10112_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","volume":"75","author":"B Gudin","year":"2020","unstructured":"Gudin B, Ladhari C, Robin P, Laroche ML, Babai S, Hillaire-Buys D et al. Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75:641\u2013647.","journal-title":"Therapie."},{"key":"10112_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534\u2013539.","journal-title":"JAMA Intern Med."},{"key":"10112_CR17","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","volume":"181","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211\u2013R234.","journal-title":"Eur J Endocrinol."},{"key":"10112_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab."},{"key":"10112_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21037\/atm.2018.02.12","volume":"6","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med. 2018;6:121.","journal-title":"Ann Transl Med."},{"key":"10112_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268\u2013274.","journal-title":"Ann Intern Med."},{"key":"10112_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403\u2013412.","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10112_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.gtc.2013.11.009","volume":"43","author":"P Chang","year":"2014","unstructured":"Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43:161\u2013173.","journal-title":"Gastroenterol Clin North Am."},{"key":"10112_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00006676-200311000-00002","volume":"27","author":"MC Dufour","year":"2003","unstructured":"Dufour MC, Adamson MD. The epidemiology of alcohol-induced pancreatitis. Pancreas. 2003;27:286\u2013290.","journal-title":"Pancreas."},{"key":"10112_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, Do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705\u2013719.","journal-title":"Lancet."},{"key":"10112_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637\u2013649.","journal-title":"Lancet."},{"key":"10112_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism. 2018;27:740\u2013756.","journal-title":"Cell metabolism."},{"key":"10112_CR27","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","volume":"310","author":"SE Kanoski","year":"2016","unstructured":"Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310:R885\u2013R895.","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"10112_CR28","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2337\/dbi21-0004","volume":"70","author":"MR Hayes","year":"2021","unstructured":"Hayes MR, Borner T, De Jonghe BC. The role of GIP in the regulation of GLP-1 satiety and nausea. Diabetes. 2021;70:1956\u20131961.","journal-title":"Diabetes."},{"key":"10112_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2337\/db15-0893","volume":"65","author":"SS Thazhath","year":"2016","unstructured":"Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65:269\u2013275.","journal-title":"Diabetes."},{"key":"10112_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","volume":"73","author":"BD Liu","year":"2024","unstructured":"Liu BD, Udemba SC, Liang K, Tarabichi Y, Hill H, Fass R et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024;73:246\u2013254.","journal-title":"Gut."},{"key":"10112_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","volume":"20","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734\u2013739.","journal-title":"Diabetes Obes Metab."},{"key":"10112_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u2013322.","journal-title":"N Engl J Med."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10112-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:23Z","timestamp":1789625123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10112-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10112"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10112-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PN, SH, JV, HKP, RN, DR, AS, SS, and MD declare no conflicts of interest.  AR is a consultant for Medtronic, ERBE, Fujifilm, Apollo Endosurgery, and Olympus. CH is a consultant for Alpha-Sigma, Fujifilm, Medtronic, Erbe, 3DMatrix, Laborie, Norgine, Olympus and Pentax. PS is a consultant for Olympus Corporation, Boston Scientific, Salix Pharmaceuticals, Cipla, Medtronic, Takeda, Samsung Bioepis, CDx, and Exact Sciences. PS has received grant support from Fujifilm, Erbe Medical, and Ironwood Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study utilized de-identified aggregate patient data from the TriNetX research network and did not involve direct human participant interaction.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized de-identified data from the TriNetX research network. TriNetX data are de-identified in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule under Section \u00a7164.514(a), with the de-identification process formally attested to through expert determination. No identifiable personal health information was accessed or used. As the study involved secondary analysis of de-identified data only, Institutional Review Board review was not sought. The study was conducted in accordance with applicable ethical standards and the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}